As their name suggests, they inhibit the degradation of acetylcholine, a molecule for the transmission between certain neurons in the brain through its synapses.
In 2004, several inhibitors have been tested and have shown some effectiveness, at least in mild to moderately severe: the donepezil, the rivastigmine and galantamine. In 2007 the French Commission of transparency reassessed four anticholinestérasiques and found a minor RAMS. According to the Journal prescribe their effects are modest, a few months in about 10% of patients.
The effect of these treatments is stabilizing and they do not cure the disease, or recover the existing level of performance at its onset. Their uses are exposed to many drug interactions and side effects. When a doctor decides to prescribe, they must be introduced as soon as possible without waiting for advanced stages of the disease.
In 2004, several inhibitors have been tested and have shown some effectiveness, at least in mild to moderately severe: the donepezil, the rivastigmine and galantamine. In 2007 the French Commission of transparency reassessed four anticholinestérasiques and found a minor RAMS. According to the Journal prescribe their effects are modest, a few months in about 10% of patients.
The effect of these treatments is stabilizing and they do not cure the disease, or recover the existing level of performance at its onset. Their uses are exposed to many drug interactions and side effects. When a doctor decides to prescribe, they must be introduced as soon as possible without waiting for advanced stages of the disease.
No comments:
Post a Comment